Event JSON
{
"id": "9ced76421f978c7be040ff8280e9610b88041ce40afd685ef5a214d355d08f91",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1743317391,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-most-expensive-230659098.html"
],
[
"subject",
"Is Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?"
],
[
"published_at",
"1743203219"
],
[
"image",
"https://s.yimg.com/ny/api/res/1.2/IL7L4DNCC04XechOcC.G2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://relay-testnet.k8s.layer3.news"
],
[
"imeta",
"url https://s.yimg.com/ny/api/res/1.2/IL7L4DNCC04XechOcC.G2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995"
],
[
"t",
"finance:perspective"
],
[
"summary",
"VRTX is a biotech company focused on developing therapies for cystic fibrosis and other diseases. Despite its strong financial performance and growth prospects, insiders have sold shares worth $10.09 million at an average price of $497.58 per share. The company's revenue growth was driven by the continued performance of TRIKAFTA/KAFTRIO, and it projects revenue to be in the range of $11.75 billion to $12 billion for the full year 2025."
]
],
"content": "nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgr8g2hyzql5lt4cxfjdj40hgtu6vydvsqvsesqy8canygcce3lwvyyapkyy\nhttps://s.yimg.com/ny/api/res/1.2/IL7L4DNCC04XechOcC.G2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995\n\nhttps://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-most-expensive-230659098.html",
"sig": "fc283ea4be5ea7b24cc77e5a73317273518b5a9d555e6e11dd0ff98a2a200c4c04ce4807d16e0a0c3c90d7cc2686ebb9113f2450df806831e37b358e93e0da21"
}